Generex Biotechnology Announces the Launch of a New Corporate Website
Press Release | 01/08/2019
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has relaunched its corporate website to provide details on a revamped organizational structure, a talented and experienced management team, and a forward-looking vision for Generex as an integrated life science holdings company. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care. You can visit the site at www.generex.com.
Generex has reorganized its portfolio of immuno-oncology assets, medical devices, and diagnostics as a family of NuGenerex subsidiary companies, and expanded the business focus through acquisitions of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization (MSO) with a network of over 400 physicians and expansion opportunities from 5 to 27 states, a network of pharmacies across the U.S., a clinical laboratory with specialty diagnostic services, and two regenerative medicine companies, Regentys and Olaregen that have been announced this week.
Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.
“We have worked diligently over the last two years on this considerable reorganization, and we are proud to share the results of our efforts and our vision for the future of Generex Biotechnology as a healthcare holding company that adds significant value for our shareholders and investors,” said Joe Moscato, CEO of Generex. “We have organized our businesses as independently operating subsidiaries under the umbrella of the NuGenerex Family of Companies, highlighting the intra-company synergies that allow for cross-company business and integrated sales. Further, we are acquiring companies like Regentys and Olaregen that fit with our strategic model to provide end-to-end solutions for patients and doctors. As you will see when you visit the site, we have transformed Generex into a new kind of healthcare company, with proprietary products and service lines that drive revenue to support the clinical development of innovative therapies and value for our investors.”
AI
